Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 32 | Alfred Chung, MDOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06623630 | Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | recruiting | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 |
| clinicaltrials |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | active not recruiting | Phase 1 / Phase 2 | 52 | Omar Nadeem, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03070327 | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | active not recruiting | Phase 1 | 100 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07169500 | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06235229 | A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma(DURGA-3) | recruiting | Phase 1 / Phase 2 | 110 | Gracell Biotechnologies (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Thomas Martin, MDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | not yet recruiting | Phase 1 / Phase 2 | 24 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Feb 19, 2026 | clinicaltrials |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07333261 | Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 25 | Susan BalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT04322292 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | completed | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | not yet recruiting | Phase 1 | 102 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 10, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT04674813 | A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 130 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT03275103 | Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | completed | Phase 1 | 355 | Genentech, Inc.INDUSTRY | 4 | Feb 5, 2026 | clinicaltrials |
| NCT06574568 | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 70 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma(iinnovate-3) | terminated | Phase 1 / Phase 2 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 7 | Jan 30, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma(iinnovate-2) | terminated | Phase 1 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 4 | Jan 29, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT07333430 | Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 60 | Hadassah Medical OrganizationOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 31 | Medical College of WisconsinOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | terminated | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 24, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT05775094 | A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | completed | Phase 1 | 31 | Fate TherapeuticsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | active not recruiting | Phase 1 | 100 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | terminated | Phase 1 | 4 | Cartesian TherapeuticsINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02937571 | High Dose Carfilzomib for Newly Diagnosed Myeloma | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2026source: clinicaltrials